Baker Bros. Advisors LP Exelixis, Inc. Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $8.15 Million - $11.5 Million	-513,410 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $12 Million - $14.6 Million	-649,234 Reduced 55.84%	513,410 $11 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $7.62 Million - $11 Million	-343,855 Reduced 22.82%	1,162,644 $25.8 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $13.9 Million - $17.8 Million	-575,513 Reduced 27.64%	1,506,499 $45.8 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $48.6 Million - $60.9 Million	2,082,012	2,082,012 $50.4 Million

504

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.